[go: up one dir, main page]

NI200600164A - Antagonistas del receptor hidroisoindolina taquiquinina - Google Patents

Antagonistas del receptor hidroisoindolina taquiquinina

Info

Publication number
NI200600164A
NI200600164A NI200600164A NI200600164A NI200600164A NI 200600164 A NI200600164 A NI 200600164A NI 200600164 A NI200600164 A NI 200600164A NI 200600164 A NI200600164 A NI 200600164A NI 200600164 A NI200600164 A NI 200600164A
Authority
NI
Nicaragua
Prior art keywords
hydroisoindoline
taquiquinine
compounds
antagonists
receiver antagonists
Prior art date
Application number
NI200600164A
Other languages
English (en)
Inventor
Jaime Lynn Bunda
Robert J Devita
Jinlong Jiang
Sander G Mills
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NI200600164A publication Critical patent/NI200600164A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se dirige a ciertos compuestos hidroisoindolina los cuales son útiles como antagonistas del receptor de la neuroquinina-1 (NK-1) e inhibidores de taquiquinina y en particular de la sustancia P. La invención también se refiere a formulaciones farmaceúticas que comprenden estos compuestos como ingredientes activos y el uso de los compuestos y sus formulaciones en el tratamiento de ciertos trastornos, incluyendo émesis, incontinencia urinaria, depresión y ansiedad.
NI200600164A 2004-01-27 2006-07-26 Antagonistas del receptor hidroisoindolina taquiquinina NI200600164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53991304P 2004-01-27 2004-01-27
US56122704P 2004-04-09 2004-04-09

Publications (1)

Publication Number Publication Date
NI200600164A true NI200600164A (es) 2007-05-29

Family

ID=34830494

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200600164A NI200600164A (es) 2004-01-27 2006-07-26 Antagonistas del receptor hidroisoindolina taquiquinina

Country Status (30)

Country Link
US (3) US7645790B2 (es)
EP (1) EP1711465B1 (es)
JP (1) JP3987100B2 (es)
KR (1) KR20060127927A (es)
AR (1) AR047439A1 (es)
AT (1) ATE382034T1 (es)
AU (1) AU2005207934B2 (es)
BR (1) BRPI0507050A (es)
CA (1) CA2554550C (es)
CO (1) CO5700771A2 (es)
CR (1) CR8522A (es)
CY (1) CY1107167T1 (es)
DE (1) DE602005004011T2 (es)
DK (1) DK1711465T3 (es)
EA (1) EA010598B1 (es)
EC (1) ECSP066716A (es)
ES (1) ES2297687T3 (es)
GE (1) GEP20094691B (es)
HR (1) HRP20080100T3 (es)
IL (1) IL176879A0 (es)
MA (1) MA28359A1 (es)
NI (1) NI200600164A (es)
NO (1) NO339041B1 (es)
NZ (1) NZ548415A (es)
PE (1) PE20050687A1 (es)
PL (1) PL1711465T3 (es)
PT (1) PT1711465E (es)
TW (1) TWI341198B (es)
UA (1) UA84192C2 (es)
WO (1) WO2005073191A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341198B (en) * 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
EP1827420A4 (en) * 2004-12-14 2009-03-04 Merck & Co Inc OCTAHYDROPYRANO [3,4-c] pyrrole tachykinin receptor Antagonist
AU2006261930B2 (en) * 2005-06-27 2011-07-14 Merck Sharp & Dohme Corp. Hydroisoindoline tachykinin receptor antagonists
AU2006269383A1 (en) * 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
CA2624440A1 (en) 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP1965794A4 (en) * 2005-12-22 2009-10-21 Merck & Co Inc OCTAHYDROPYRANO [3,4-c] pyrrole tachykinin receptor Antagonist
EP1978965A2 (en) * 2006-01-24 2008-10-15 Merck & Co., Inc. Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) * 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
CA2683584C (en) * 2007-04-10 2015-07-07 Merck & Co., Inc. Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
EP3013336A1 (en) * 2013-06-24 2016-05-04 Tigercat Pharma Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
EA202090180A1 (ru) 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
IL296635A (en) 2020-04-03 2022-11-01 Nerre Therapeutics Ltd An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650142A (en) * 1995-09-27 1997-07-22 Church & Dwight Co., Inc. Bicarbonate-containing deodorant cosmetic stick compositions
JP2002534955A (ja) * 1995-10-18 2002-10-15 メルク エンド カンパニー インコーポレーテッド シクロペンチルタキキニン受容体アンタゴニスト
EP1670476A4 (en) 2003-09-30 2009-05-27 Merck & Co Inc Phenylpyrrolidine-ETHER-tachykinin receptor Antagonist
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists

Also Published As

Publication number Publication date
TWI341198B (en) 2011-05-01
EA010598B1 (ru) 2008-10-30
AR047439A1 (es) 2006-01-18
ECSP066716A (es) 2006-10-31
CA2554550A1 (en) 2005-08-11
EP1711465B1 (en) 2007-12-26
AU2005207934B2 (en) 2010-11-25
AU2005207934A1 (en) 2005-08-11
US7645790B2 (en) 2010-01-12
PL1711465T3 (pl) 2008-05-30
PT1711465E (pt) 2008-02-25
KR20060127927A (ko) 2006-12-13
ATE382034T1 (de) 2008-01-15
CR8522A (es) 2007-06-06
DK1711465T3 (da) 2008-03-31
GEP20094691B (en) 2009-05-25
US7345083B2 (en) 2008-03-18
MA28359A1 (fr) 2006-12-01
TW200534850A (en) 2005-11-01
HRP20080100T3 (en) 2008-04-30
NO20063810L (no) 2006-10-26
US7217731B2 (en) 2007-05-15
US20070161695A1 (en) 2007-07-12
PE20050687A1 (es) 2005-09-27
CA2554550C (en) 2011-05-03
US20080280966A1 (en) 2008-11-13
EA200601378A1 (ru) 2007-02-27
DE602005004011T2 (de) 2008-12-11
US20050165083A1 (en) 2005-07-28
NZ548415A (en) 2009-11-27
JP2007519728A (ja) 2007-07-19
NO339041B1 (no) 2016-11-07
HK1100937A1 (zh) 2007-10-05
EP1711465A1 (en) 2006-10-18
JP3987100B2 (ja) 2007-10-03
CO5700771A2 (es) 2006-11-30
CY1107167T1 (el) 2012-10-24
IL176879A0 (en) 2006-10-31
BRPI0507050A (pt) 2007-06-12
UA84192C2 (en) 2008-09-25
DE602005004011D1 (de) 2008-02-07
WO2005073191A1 (en) 2005-08-11
ES2297687T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
NI200600164A (es) Antagonistas del receptor hidroisoindolina taquiquinina
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY28760A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
CR8847A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos
ECSP056097A (es) Antagonistas del receptor cgrp
UY28150A1 (es) Agentes terapeuticos
GT200800227A (es) Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
AR055123A1 (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica
WO2005032464A3 (en) Phenyl pyrrolidine ether tachykinin receptor antagonists
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
WO2007002457A3 (en) Hydroisoindoline tachykinin receptor antagonists
WO2006065711A3 (en) Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
NO20070355L (no) Lactamforbindelser som tachykininreseptorantagonister
WO2006060346A3 (en) 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
WO2007136570A3 (en) 5,6-fused pyrrolidine compounds useful as tachykinin receptor antagonists
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten